New risk markers found for liver cancer patients getting combined therapy

For people living with intermediate or advanced liver cancer, knowing who might struggle with the disease is vital. A recent look at 243 patients receiving a combination of TACE and targeted immunotherapy revealed specific warning signs. The team found that high bilirubin, elevated D-dimer, and tumors blocking the portal vein were independent risk factors for the cancer advancing. These markers help doctors see who is at higher risk for tumor progression over six, 12, and 24 months. The researchers also used a screening method called LASSO regression to find ten other important factors, including albumin levels, white blood cell counts, and tumor size. Together, these ten factors showed good ability to distinguish between patients with different outcomes. This information helps guide individualized treatment decisions for those facing this serious illness. While the study did not report specific safety issues or side effects, understanding these risk markers allows for more careful planning of care.